Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

Highly efficient new generation synthetic RNA-replicon based vaccine

Objetivo

The project seeks to create a novel, efficacious vaccine against influenza virus; a new type of synthetic vaccine readily adaptable to meet whichever influenza virus subtype may arise. A new generation of RNA-replicon technology will be employed combined with nanoparticles and innovative adjuvants for targeting of dendritic cells and efficient antigen expression. The consortium comprises two SMEs and two academic institutions each having unique and patented expertise such as replicon technology, nanoparticle technology, adjuvant chemistry, and surface modification chemistry to attach targeting moieties. As a highly interdisciplinary project, extensive exchange of knowledge between the project partners will be required in particular between product focused SMEs (nanoparticles, adjuvants) and technology excellence of academic institutions (replicon technology, surface modification chemistry).

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-PEOPLE-2009-IAPP
Consulte otros proyectos de esta convocatoria

Régimen de financiación

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinador

THE UNIVERSITY OF MANCHESTER
Aportación de la UE
€ 799 522,00
Dirección
OXFORD ROAD
M13 9PL Manchester
Reino Unido
Región
North West (England) Greater Manchester Manchester
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Participantes (3)